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Systemic treatment of malignant gastrointestinal 
neuroectodermal tumour after childhood neuroblastoma: 
chemotherapy in malignant gastrointestinal neuroectodermal 
tumour
Margaret Ottavianoa,b, Chiara Maddalenaa, Maria D’Armientoc,  
Rossella Lauriaa, Vincenzo D’Alessandrod, Marianna Tortorab,  
Elide Matanoa, Vincenzo Di Lauroa, Brigitta Muccia, Gabriella Ferraroe,  
Sabino De Placidoa,b, Mario Giulianoa,b and Giovannella Palmierib    
Malignant gastrointestinal neuroectodermal tumour 
is an extremely rare neoplasm that arises in the wall 
of the small bowel, stomach or large bowel in young-
aged and middle-aged adults. Histologically, it is 
generally characterized by monomorphic cells with clear 
cytoplasma, S-100 protein expression, and EWSR1 gene 
translocation. To the best of our knowledge, we describe 
for the first time, the case of a young woman with a 
diagnosis of metastatic gastrointestinal neuroectodermal 
tumour arising from ileum, who had a childhood adrenal 
neuroblastoma with liver, bone and lymph nodes 
metastasis, treated with four cycles of chemotherapy 
with the schedule CADO-CVP (CADO: cyclophosphamide 
300 mg/m2/day on days 1–5, vincristine 1,5 mg/m2/
day on days 1 and 5, and doxorubicin 60 mg/m2/day on 
day 5; CVP: cisplatin 40 mg/m2/day on days 1–5 and 
etoposide 100 mg/m2/day on days 1–5) followed by right 
adrenal, kidney, lymph nodes and liver lesion resection, 
conditioning chemotherapy (melphalan-carmustine-
teniposide), stem cells autologous transplantation 
and consecutively radiotherapy on the spine (T9 to 
L3) for a total of 30 Gy. For the second diagnosis of 
gastrointestinal neuroectodermal tumour with liver 
metastasis, she underwent ileal tumour resection and 
platinum-anthracycline based chemotherapy with initial 
shrinkage of liver metastasis. Unfortunately, despite the 
initial response and the following delivered therapies, she 
died for rapid progressive disease. Taking into account 
the late effects of past therapeutic modalities, a long-term 
surveillance of young child treated for neuroblastoma, 
is required to appreciate their overall risks of second 
malignancies.  
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Introduction
Malignant gastrointestinal neuroectodermal tumour 
(GNET) is an extremely rare neoplasm that arises in 
the wall of the small bowel, stomach or large bowel in 
young-aged and middle-aged adults. Histologically, it is 
generally characterized by monomorphic cells with clear 
cytoplasma, S-100 protein expression, and EWSR1 gene 
translocation, sharing these features with the more known 
entity, the clear cell sarcoma (CCS)-like of the gastroin-
testinal tract (CCSLGT), from which, however, differs 
for the evidence of neuroectodermal differentiation. The 
exact nosological relationship between these rare tumours 
is still matter of debate. Differently, from the CCS of 
soft tissue and of tendons and aponeuroses, which usu-
ally shows a less progressive and aggressive course and 
presents the immuno-histochemical or ultrastructural 
melanocytic differentiation, GNET and CCSLGT clearly 
share a poor prognosis [1]. Because of the aggressive 
biological behaviour, GNET is diagnosed more often at 
metastatic stage, and, since no medical standard therapy 
has been approved as patients rapidly progress, the sur-
gery remains the only available treatment. To the best of 
our knowledge, we describe, for the first time, the unique 
case of a 28-year-old female, with a previous diagnosis of 
childhood neuroblastoma, who achieved partial response 
of metastatic GNET with systemic chemotherapy.
Case report
In December 2014, after the onset of persistent anae-
mia, night sweats and hyperpyrexia, a 28-year-old white 
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female underwent clinical and instrumental examina-
tions that showed a small bowel mass and several suspi-
cious liver lesions (Fig. 1). In March 2015, ileal resection 
with end-to-end anastomosis was performed to avoid 
the risk of intestinal sub-occlusion and considering the 
persistence of anaemia, hepatic metastasectomy was not 
performed, due to the number and size of liver lesions. A 
deeply histological exam was carried on. Microscopically 
the mass was composed of large nests of markedly atyp-
ical cells, which occasionally were disposed in a pseu-
doalveolar and pseudopapillary pattern (Fig.  2a and 
b). Mitoses were frequent, as well as cell cannibalism 
(Fig.  2b). A broad immunohistochemical (IHC) panel 
was performed: neoplastic cells were Cytokeratin, LCA, 
NSE, HMB45, Melan-A, Chromogranine, Bcl2, CD34, 
CD99, EMA, CD117, Actin, Desmin, CD68 negative, 
but showed positivity for protein S-100 (Fig. 3a), CD56 
(Fig.  3b), synaptophysin (Fig.  3c), Vimentin. Neither 
melanotic pigment was seen, nor histiocytic giant cells. 
All lymph nodes isolated from the perivisceral fat were 
metastatic. Fluorescent In Situ Hybridization analysis 
revealed EWSR1-CREB1 fusion, with disruptions of 
both EWSR1 (22q12) and CREB1 (2q33) demonstrated. 
The whole data were suggestive of malignant GNET.
The post-operative contrast-enhanced computed tomog-
raphy (CT) scan confirmed unresectable multiple liver 
metastases, the symptoms of anaemia, night sweats and 
hyperpyrexia, were still present, the decision of starting 
systemic chemotherapy was made. The patient received 
three cycles of cisplatin 30  mg/m2; doxorubicin 20  mg/
m2 on days 1–3, with granulocyte-colony stimulating fac-
tor administration. Restaging scans showed a reduction 
in number and size of the known liver lesions (Fig.  4a 
and b). No further chemotherapy in according to that 
schedule was delivered, taking into account the cumula-
tive dose of cytotoxic drugs previously administered for 
the diagnosis of childhood neuroblastoma. The patient, 
in fact, reported a history of adrenal neuroblastoma with 
liver, bone and lymph nodes metastasis at the age of 2 
years old. A complete remission was achieved after four 
cycles of chemotherapy with the schedule CADO-CVP 
(CADO: cyclophosphamide 300  mg/m2/d on days 1–5, 
vincristine 1.5 mg/m2/day on days 1 and 5, and doxoru-
bicin 60 mg/m2/day on day 5; CVP: cisplatin 40 mg/m2/
day on days 1–5 and etoposide 100 mg/m2/day on days 
1–5) followed by right adrenal, kidney, lymph nodes and 
liver lesions resection, conditioning chemotherapy (mel-
phalan-carmustine-teniposide), stem cells autologous 
Fig. 1
Contrast-enhanced abdomen CT scan: evidence of ileal mass. CT, 
computed tomography.
Fig. 2
(a) Haematoxylin-eosin stain (100×), pseudopapillary pattern. (b) Haematoxylin-eosin stain (100×), pseudoalveolar pattern and large solid nests. 
There are distinctive cellular atypia and cell cannibalism.
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transplantation and consecutively radiotherapy on 
the spine (T9 to L3) for a total of 30 Gy. The patient 
remained free of disease, and at the age of 18 was dis-
charged from periodical follow-up. In September 2015, 
after discontinuation of cisplatinum- anthracycline based 
chemotherapy, a new CT scan showed local relapse and 
liver disease progression. Patient started treatment with 
sunitinib 37.5  mg daily, withdrawn after 1 month due 
to severe thrombocytopenia, anaemia and new onset of 
hyperpyrexia. Technetium-labelled erythrocyte scintig-
raphy showed uptake in the hepatic region. Selective 
arteriography and arterial embolization of right lumbar 
artery were performed, the following abdominal CT scan 
revealed blood dripping of a new hepatic lesion and fur-
ther liver, peritoneal and nodal disease progression. The 
patient sadly died 4 weeks later.
Discussion
GNET is an extremely rare malignant neoplasm that 
occurs predominantly in young-aged and middle-aged 
adults, with no sex preponderance noted [1]. As a new dis-
ease entity recently described, GNET develops mostly in 
the wall of the small bowel with a high rate of local recur-
rence, usually developing lymph nodes and liver metas-
tases. Differently from any other primitive malignancies 
of the gastrointestinal tract, it shares morphological and 
molecular features with the CCSLGT like the absence 
of melanocytic differentiation, the chromosomal trans-
location involving EWSR1-ATF1 (12;22) (q13;q12) and 
the symptomatic picture of abdominal pain, sub-occlu-
sive syndrome, anorexia, weight loss, anaemia, lethargy, 
pyrexia and night sweats [1]. GNET might be consid-
ered a neuroectodermal tumour with aggressive behav-
iour and poor prognosis in contrast to the longer survival 
of patients with conventional CCS [2]. Firstly described 
by Enzinger in 1965, CCS is a deep soft tissue tumour 
associated with tendons and aponeuroses [3]. In 1993, the 
first visceral case of CCS in the duodenum was reported 
[4], and due to the lack evidence of melanocytic differ-
entiation of the CCS occurring in the gastrointestinal 
Fig. 3
(a) Immunohistochemical stain (100×): S100 positive. (b) Immunohistochemical stain (100×): synaptophysin positive. (c) Immunohistochemical 
stain (100×): CD56 positive.
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tract, some authors proposed the definition of CCS-like 
tumour of the gastrointestinal tract CCSLTGT. First 
described by Zambrano et al. in 2003 [5], this new entity 
is composed, histologically, of relatively monomorphic 
ovoid or round cells with clear to eosinophilic cyto-
plasm, arranged in sheets or more ill-defined nests and 
sometimes it presents papillary or alveolar architectures 
[5,6], often with occasionally osteoclast-like giant cells 
in variable numbers [5,7–9]. CCSLGT is focally posi-
tive for S100 protein, but does not express melanocytic 
markers such as HMB45 or Melan-A. In case of neu-
roendocrine markers expression, such as synaptophysin, 
chromogranin, NSE or CD56, it has been proposed that 
CCSLGT might be re-designated as gastrointestinal 
neuroectodermal tumour (GNET) [2,10]. In fact, very 
recently, Stockman et  al. [2] described 16 cases of gas-
trointestinal malignancies with morphologic and molec-
ular features similar to those described in CCSLTGT 
with a primitive neural phenotype for the IHC profile: 
positivity for S100, SOX10, NSE, synaptophysin, CD56 
and NB84 and negativity for HMB45, melan-A, tyrosi-
nase. Since this rare entity do not have a normal cellular 
counterpart, and an origin from a gastrointestinal neuro-
ectodermal precursor cell has been postulated, the desig-
nation of Malignant GNET has been approved [2]. We 
describe a unique case of GNET, arising in the ileum of 
a 28-year-old white female, who previously underwent 
high dose chemotherapy and radiation therapy for a 
childhood adrenal neuroblastoma. No standard medical 
treatment is available for GNET due to the poor prog-
nosis and short survival. In this exposed case, taking into 
account the clinical stability, the young age of the patient 
and the available literature data, we decided to deliver 
platinum-anthracycline- systemic chemotherapy. Jones 
et  al. reported the Memorial Sloan-Kettering Cancer 
Center experience of 24 CCS patients treated with pal-
liative first-line chemotherapy. With a median progres-
sion-free survival of 11 weeks [95% confidence interval 
(CI), 3–20 weeks] and a median overall survival of 39 
weeks (95% CI, 34–45 weeks), the best tumour control 
was reached with anthracycline-based schedules [11], 
as well as in The Japanese Musculoskeletal Oncology 
Group report of 30 adult with metastatic CCS, the best 
outcome of partial response was achieved in seven of 
these patients treated with  cisplatin-based chemother-
apy [12]. In our case, after the combination of cisplatinum 
and anthracycline-based chemotherapy a liver metastasis 
reduction was obtained, as well as a symptomatic relief 
was observed with disappearance of fever, night sweats 
and anaemia. Unfortunately, taking into account the 
cumulative dose of cytotoxic drugs previously adminis-
tered for the diagnosis of childhood neuroblastoma, the 
decision of stopping chemotherapy was made, and at 
further progression sunitinib was prescribed. However, 
in contrast with some literature data [13] she reported a 
rapid disease progression.
Although reported cases of CCSLGT have occurred as 
second malignancies following irradiation and chemo-
therapy for neuroblastoma (two cases) [14,15] and hepa-
toblastoma [16], to the best of our knowledge, no case of 
GNET after childhood neuroblastoma has been reported. 
We envision our case might help to shed on light on the 
etiology of this rare neoplasm, suggesting that previous 
treatments in childhood can be possible precipitating fac-
tors for GNET development later in life. Rubino et  al. 
analysed data of 544 childhood survivors of neuroblastoma 
Fig. 4
(a) Contrast-enhanced abdomen CT scan: liver lesion before chemotherapy. (b) Contrast-enhanced abdomen CT scan: liver lesion after 
 chemotherapy. CT, computed tomography.
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and found 13-second malignant neoplasms (SMNs). The 
median time from diagnosis of neuroblastoma and occur-
rence of a SMN was 19.5 years (range 5–37 years). The 
most common SMNs included thyroid, breast and leu-
kemia. Twelve of 13 patients with SMN received radi-
otherapy, while only three received chemotherapy. Five 
of those receiving radiotherapy developed a SMN within 
the radiation field, suggesting that irradiation may be an 
important risk factor [17]. Although no case of gastroin-
testinal sarcoma has been reported in this series, and the 
impact of chemo and radiotherapy combination in our 
patient is difficult to determine, the time and the ana-
tomic region of SMN may highlight a link of cause-effect.
Conclusion
GNET is a rare malignant neoplasm with very poor prog-
nosis. Conventional chemotherapy has little role in the 
treatment of this entity; further experience is awaited 
to define optimal treatment strategies for GNET and to 
evaluate the role of platinum and anthracycline-based 
therapy. The development of second malignancies many 
years after neuroblastoma emphasizes the necessity of 
long-term surveillance in childhood cancer survivors and 
highlights the potential impact of therapeutic decisions.
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